TESTING PARTNER OF THE LPGA TOUR

LPGA_LOGO_VERT_Color_over_White.png Eurofins Named Official Testing Partner of the LPGA Tour DAYTONA BEACH, Fla., Sept. 23, 2020 – The Ladies Professional Golf Association (LPGA) today announced that Eurofins has been named the Tour’s Official Testing Partner. Eurofins, a world leader in clinical diagnostics, forensic, pharmaceutical, food and environmental laboratory testing services, will leverage the Eurofins SAFER@WORKTM protocols to aid in the Tour’s continued safe return to play. The partnership, slated to run through 2021, will ensure the LPGA has an easy, painless, fast and reliable COVID-19 testing program. “The health and safety of our athletes, caddies, staff and tournament partners is always our number one priority, and it was very important for us to find a global testing partner that would help fit our needs in the United States and internationally. As a world-wide leader in bio-analysis, Eurofins is a perfect match for our global Tour and schedule,” said Heather Daly-Donofrio, LPGA Chief Tour Operations Officer. “We are excited to welcome Eurofins to the LPGA family as we work to maintain a safe and healthy tournament environment each week on Tour.” Players, caddies, staff and essential personnel will take self-administered, mid-nasal polymerase chain reaction (PCR) tests at an on-site testing location upon tournament arrival. Direct pathogen detection via PCR is the industry method of choice to detect acute COVID-19 infection. Eurofins will leverage its global network of laboratories to offer the LPGA a dedicated on-site team to monitor sample collection at each tournament and provide results within 24-48 hours. Eurofins has been at the forefront of COVID-19 testing – launching its first RT-PCR (real-time reverse-transcriptase polymerase chain reaction) assay for SARS-CoV-2 on March 13. Since then, Eurofins has rolled out several highly accurate, FDA-approved active infection and antibody assays to thousands of clients nationwide, including hospitals, physicians’ offices, nursing homes, government entities, sports organizations and employers. In addition to individual PCR testing, Eurofins offers a robust group of assays for COVID-19, including pooled, antibody, wastewater, worn-mask, and environmental surfaces and will soon be launching saliva testing. About Eurofins – the global leader in bio-analysis Eurofins Scientific, through its subsidiaries (hereinafter “Eurofins” or “the Group”), believes it is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric and molecular clinical diagnostic testing. With over 48,000 staff across a network of more than 900 independent companies in over 50 countries generally specialized by end client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services. The Group’s objective is to provide customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly-qualified staff. Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods. As one of the most innovative and quality-oriented international groups in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world. Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP). About the LPGA The LPGA is the world’s leading professional golf organization for women. Founded in 1950 and headquartered in Daytona Beach, Fla., the association celebrates a diverse and storied membership with more than 2,300 members representing more than 30 countries. With a vision to inspire, empower, educate and entertain by showcasing the very best of women’s golf, LPGA Tour Professionals compete across the globe, while the Symetra Tour, the official development and qualifying tour of the LPGA, consistently produces a pipeline of talent ready for the world stage. Additionally, LPGA Professionals directly impact the game through teaching, coaching and management. The LPGA demonstrates its dedication to the development of the game through The LPGA Foundation. Since 1991, this charitable organization has been committed to empowering and supporting girls and women through developmental and humanitarian golf initiatives, such as LPGA*USGA Girls Golf, the LPGA Women’s Network and the LPGA Amateur Golf Association. Follow the LPGA on its television home, Golf Channel, and on the web via www.LPGA.com. Join the social conversation at www.facebook.com/lpga, www.twitter.com/lpga and www.youtube.com/lpgavideo, and on Instagram at @lpga_tour.